{"id":"W4399519585","doi":"10.1200/jco.2024.42.16_suppl.tps8116","title":"The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003791425,0.003687012,0.002672829,0.0005617341,0.0004135703,0.001601449,0.001533611,0.002180573,0.01061464],"category_scores_gemma":[0.00169967,0.0009132918,0.002986027,0.0004668905,0.001255194,0.001290248,0.0007656026,0.004986361,0.002192528],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001438989,"about_ca_system_score_gemma":0.001879596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064806,"about_ca_topic_score_gemma":0.002238775,"domain_scores_codex":[0.9989166,0.0006321293,0.00003148306,0.0001651686,0.00006437696,0.0001902355],"domain_scores_gemma":[0.9990633,0.0002100468,0.000234894,0.0001011114,0.00005654976,0.0003340895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9693735,0.01258602,0.0006988133,0.0003838583,0.001111618,0.00004043231,0.00004223166,0.0007034195,0.004634668,0.0002286705,0.001741028,0.008455637],"study_design_scores_gemma":[0.7828549,0.2080011,0.002882847,0.00003458179,0.001110756,0.00006005905,0.00003625465,0.001042732,0.001397765,0.0004110138,0.002138366,0.00002960492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"methods","genre_scores_codex":[0.967997,0.003048399,0.001715087,0.001356547,0.001201191,0.01291337,0.004421223,0.000257825,0.007089389],"genre_scores_gemma":[0.9402639,0.001973946,0.004964392,0.002923127,0.001317976,0.02512572,0.005617774,0.0001250921,0.01768804],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01061464,"threshold_uncertainty_score":0.03550947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1331790561597407,"score_gpt":0.4799944488978683,"score_spread":0.3468153927381276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}